Targeted Therapy and Immunosuppression in the Tumor Microenvironment

Trends in Cancer

Volumn 3, Issue 1, 2017, Pages 19-27

  Allegrezza, Michael J ^a   Conejo Garcia, Jose R ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

cancer immunotherapy; small molecule inhibitors; targeted therapies; tumor microenvironment

Indexed keywords

ADAPTIVE IMMUNITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECT; IMMUNOLOGY; NEOPLASM;

ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOSUPPRESSION; MOLECULAR TARGETED THERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85009431331     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.11.009     Document Type: Review

References (74)

1. 1 Sierra, J.R., et al. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer, 9, 2010, 75.
2. 2 Vesely, M.D., et al. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29 (2011), 235–271.
3. 3 Topalian, S.L., et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
4. 4 Knight, D.A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123 (2013), 1371–1381.
5. 5 Allegrezza, M.J., et al. Trametinib drives T-cell-dependent control of KRAS-mutated tumors by inhibiting pathological myelopoiesis. Cancer Res. 76 (2016), 6253–6265.
6. 6 Woods, D.M., et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 23 (2013), 341–348.
7. 7 Wang, Q., et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 72 (2012), 4417–4428.
8. 8 Zhang, L., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 (2003), 203–213.
9. 9 Salgado, R., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in her2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial. JAMA Oncol. 1 (2015), 448–454.
10. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 (1998), 3491–3494.
11. + T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61 (2001), 5132–5136.
12. 12 Lee, N., et al. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 48 (2016), 177–187.
13. 13 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
14. 14 Smith-Garvin, J.E., et al. T cell activation. Annu. Rev. Immunol. 27 (2009), 591–619.
15. 15 Allegrezza, M.J., et al. Il-15 agonists overcome the immunosuppressive effects of Mek inhibitors. Cancer Res. 76 (2016), 2561–2572.
16. 16 Boni, A., et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70 (2010), 5213–5219.
17. 17 So, L., et al. Selective inhibition of phosphoinositide 3-kinase p110alpha preserves lymphocyte function. J. Biol. Chem. 288 (2013), 5718–5731.
18. 18 Blanco, B., et al. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function. Int. Immunopharmacol. 28 (2015), 675–685.
19. 19 Wong, D.J., et al. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol. Res. 2 (2014), 459–468.
20. 20 Schmudde, M., et al. Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions. Cancer Lett. 295 (2010), 173–181.
21. 21 Nellore, A., et al. The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors. Clin. Immunol. 152 (2014), 48–57.
22. 22 Yamaguchi, T., et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide. Inflamm. Res. 61 (2012), 445–454.
23. 23 Hu-Lieskovan, S., et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med., 7, 2015, 279ra241.
24. 24 Liu, L., et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21 (2015), 1639–1651.
25. 25 Riley, J.L., PD-1 signaling in primary T cells. Immunol. Rev. 229 (2009), 114–125.
26. 26 Patsoukis, N., et al. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell Biol. 33 (2013), 3091–3098.
27. 27 Peng, W., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6 (2016), 202–216.
28. 28 Bedard, P.L., et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res. 21 (2015), 730–738.
29. 29 Du Four, S., et al. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology, 4, 2015, e998107.
30. 30 So, L., Fruman, D.A., PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem. J. 442 (2012), 465–481.
31. 31 Martin, A.L., et al. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase. J. Immunol. 180 (2008), 2081–2088.
32. 32 Okkenhaug, K., Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31 (2013), 675–704.
33. 33 Fruman, D.A., Rommel, C., PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13 (2014), 140–156.
34. 34 Callahan, M.K., et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol. Res. 2 (2014), 70–79.
35. + T cells by modulating cholesterol metabolism. Nature 531 (2016), 651–655.
36. 36 Kay, J.E., et al. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 72 (1991), 544–549.
37. 37 Araki, K., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460 (2009), 108–112.
38. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 9571–9576.
39. 39 Diken, M., et al. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol. Res. 1 (2013), 386–392.
40. 40 Shindo, T., et al. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner. Blood 121 (2013), 4617–4626.
41. 41 Abu-Eid, R., et al. Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway. Cancer Immunol. Res. 2 (2014), 1080–1089.
42. 42 Zwang, N.A., et al. Selective sparing of human Tregs by pharmacologic inhibitors of the PI3-kinase and MEK pathways. Am. J. Transplant. 16 (2016), 2624–2638.
43. + regulatory T cells. Blood 105 (2005), 4743–4748.
44. 44 Hasty, P., et al. eRapa restores a normal life span in a FAP mouse model. Cancer Prev. Res. 7 (2014), 169–178.
45. 45 Soond, D.R., et al. Does the PI3K pathway promote or antagonize regulatory T cell development and function?. Front. Immunol., 3, 2012, 244.
46. 46 Sauer, S., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 7797–7802.
47. 47 Terme, M., et al. VEGFA–VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73 (2013), 539–549.
48. 48 Adotevi, O., et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33 (2010), 991–998.
49. 49 Svoronos, N., et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov., 2016, 10.1158/2159-8290.CD-16-0502 Published online September 30, 2016.
50. 50 Solito, S., et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 1319 (2014), 47–65.
51. 51 Kumar, V., et al. CD45 Phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity 44 (2016), 303–315.
52. 52 Yuan, H., et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomed. Pharmacother. 68 (2014), 751–756.
53. 53 Espagnolle, N., et al. Specific inhibition of the VEGFR-3 tyrosine kinase by SAR131675 reduces peripheral and tumor associated immunosuppressive myeloid cells. Cancers 6 (2014), 472–490.
54. 54 Serafini, P., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203 (2006), 2691–2702.
55. 55 Hsu, C.L., et al. Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. Blood 110 (2007), 1420–1428.
56. 56 Youn, J.I., et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat. Immunol. 14 (2013), 211–220.
57. 57 Vella, L.J., et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol. Res. 2 (2014), 351–360.
58. + polyfunctional T cells that mediate rejection of murine tumors. Cancer Res. 72 (2012), 581–591.
59. 59 Borg, C., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114 (2004), 379–388.
60. 60 Wang, H., et al. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J. Immunol. 186 (2011), 3986–3996.
61. 61 Leone, R.D., et al. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput. Struct. Biotechnol. J. 13 (2015), 265–272.
62. 62 Iannone, R., et al. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15 (2013), 1400–1409.
63. 63 Zheng, H., et al. HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 22 (2016), 4119–4132.
64. 64 Skov, S., et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65 (2005), 11136–11145.
65. 65 Armeanu, S., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65 (2005), 6321–6329.
66. 66 Schumacher, L.Y., et al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341 Velcade). J. Immunol. 176 (2006), 4757–4765.
67. 67 Shanker, A., et al. Bortezomib improves adoptive T-cell therapy by sensitizing cancer cells to FasL cytotoxicity. Cancer Res. 75 (2015), 5260–5272.
68. 68 Zhao, T., et al. Inhibition of HIF-1alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 6 (2015), 2250–2262.
69. 69 Galluzzi, L., et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28 (2015), 690–714.
70. 70 Rohle, D., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 (2013), 626–630.
71. 71 Wang, F., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340 (2013), 622–626.
72. 72 Bodenmiller, B., et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat. Biotechnol. 30 (2012), 858–867.
73. 73 Ho, P.C., et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res. 74 (2014), 3205–3217.
74. 74 Steinberg, S.M., et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol. Res. 2 (2014), 1044–1050.